Your browser does not support JavaScript!
:::
Examinee
:::
Ann-Joy Cheng

Ann-Joy Cheng

Highest Degree

Ph. D. in Tumor Biology MD Anderson Cancer Center

Areas of Specialty

Tumor Biology Medical Biotechnology Cell / Molecular Biology

Office Phone

5085

Lab phone

5216

Research website:

http://mip.cgu.edu.tw/files/13-1035-12160.php?

E-mail

ajchenmail.cgu.edu.tw

Lab & Research Interest

Research interests

We, Laboratory of Translational Cancer Research are to investigate clinical associated cancer issues, especially on the topic of native Taiwan cancer Head and neck cancer (HNC). HNC, including oral cavity cancer and pharyngolaryngeal cancer, is one of the ten frequent cancers in the world with an estimated over 500,000 new cases being diagnosed annually. In Taiwan, the incidence of HNC has become the top 5th cancer in male after year of 2006, and is still increasing in recent years. Since this cancer usually occurs in the middle age male, at the high peak of life responsibility, it has tremendous impact of family and society. Epidemiologic studies have shown a wide variation range of incidence between worldwide areas. HNC is highly prevalent in Southeast Asia, comprising 30-35% of all malignancies in India, compared to approximately 10% in Taiwan and 2-4% in Western countries. Epidemiologic studies have shown a strong association between HNC and environmental carcinogens, especially the use of tobacco, alcohol, and areca nut. While tobacco smoking is a common habit in Western patients, areca nut chewing inIndia area, the both habits are frequently found In Taiwan patients. Therefore, the differential incidence of HNC may be attributed to certain environmental exposures, in addition to genetic factors.

        According to specific tumor subsite and individual clinical behavior, the treatment of HNC usually integrates with surgery, chemotherapy, and radiotherapy. In order to better serve patients and more comprehensively study this disease, we together with other multidisciplinary investigators and clinical physicians form the Chang Gung Head Neck Oncology Group. The goal of our laboratory is to systemic investigate the molecular carcinogenesis of HNC. The research topics include the carcinogenic mechanism of areca nut, searching of circulating tumor markers, identification of molecular pathogenic networks, and evaluations of prognostic factors. To reach these goals, we have established several HNC cell lines, as well as sublines with the characteristics of highly invasion, radioresistance, chmeoresistance, and chronic area nut exposure. We used advanced techniques, including microarray and bioinformatic analyses to global survey and profile the transcriptomes and proteomes of each specific cellular phenotype. We then used cellular and animal based methods to examine the molecular network pathways and biological functions of the genes that we defined. Finally, we performed clinical association study to evaluate the significance of the identified genes in clinicopathological presentations. Currently, several molecules that were first determined by us demonstrate contributing to HNC, such as DSG3, Grp78, and Gp96. They functions on cellular metastasis, cancer stem cell conversion, and radio-resistance, respectively. We hope the results of our study can contribute to the knowledge in cancer field, as well further apply in clinical diagnosis, therapeutics, and prognosis to benefit medical society.

Publication

  1. Lin CY, Chen WH, Liao CT, Chen IH, Chiu CC, Wang HM, Yen TC, Lee LY, Chang JT, Cheng AJ*. Positive association of GRP78 during oral cancer progression and the prognostic value in oral precancer lesions. Head Neck 2009 Dec 1. [Epub ahead of print].
  2. Wu YH, Wang HM, Chen HW, Lin CY, Chen YE, Fan KH, Huang SF, Chen IH, Liao CT, Cheng AJ, Chang JT. Hypothyroidism After Radiotherapy for Nasopharyngeal Cancer Patients. Int J Radiat Oncol Biol Phys. 2009 Jul 11. [Epub ahead of print]
  3. Kang CJ, Chen YJ, Liao CT, Wang HM, Chang JT, Lin CY, Lee LY, Wang TH, Yen TC, Shen CR, Chen IH, Chiu CC, Cheng AJ*. (2009, 11) Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer. Cancer Lett. 284: 131-140.
  4. Chao YK, Yeh CJ, Chuang WY, Fan KH, Hsieh MJ, Chu Y, Cheng AJ, Liu HP. (2009, 12) Prognostic significance of immunohistochemically detected lymph node micrometastases in pT0N0 esophageal squamous cell carcinoma. J Surg Oncol. 100: 559-562.
  5. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. (2009, 7) Preoperative [18F]Fluorodeoxyglucose Positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 74: 1054-1061.
  6. Liao CT, Chang JT, Wang HM, Ng SH, Huang SF, Chen IH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Yen TC. (2009, 11) Preoperative [(18)F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse. Eur J Nucl Med Mol Imaging 36: 1783- 1793.
  7. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF,Cheng AJ, Yen TC. (2009, 6) Preoperative [18F]fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 74:1054-1061.
  8. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, See LC, Yen TC. (2009, 3) Pretreatment primary tumor SUVmas measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 73: 764-771.
  9. Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Yen TC. (2009, 1) Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery. Ann Surg Oncol 16: 159-170.
  10. Chiu CC, Lin CY, Lee LY, Chen YJ, Kuo TF, Chang JTC, Liao CT, Wang HM, Yen TC, Shen CR, Liao SK, Cheng AJ*. (2008, 9) Glucose-regulated protein 78 regulates multiple malignant phenotypes in head-neck cancer and may serve as a molecular target of therapeutic intervention. Mol Cancer Ther 7: 2788-2797.
  11. Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Yen TC. (2008, 8) When does skin excision allow the achievement of an adequate local control rate in patients with squamous cell carcinoma involving the buccal mucosa? Ann Surg Oncol 15: 2187-2194.
  12. Chen YJ, Chang JTC, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, Cheng AJ*. (2008, 8) Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 99: 1507-1514.
  13. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, See LC, Yen TC. (2008, 6) Does adjuvant radiation therapy improve outcome in pT1-3N0 oral cavity cancer with tumor-free margins and perineural invasion? Int J Radiat Oncol Biol Phys 71: 371-376.
  14. Lin CY, Lee LY, Huang SF, Kang CJ, Fan KH, Wang HM, Chen EY, Chen IH, Laio CT, Cheng AJ, Chang JT. (2008, 4) Treatment outcome of combined modalities for buccal cancer: unilateral or bilateral neck radiation? Int J Radiat Oncol Biol Phys 70: 1373-1381.
  15. Huang SF, Kang CJ, Lin CY, Fan KH, Yen TC, Wang HM, Chen IH, Liao CT, Cheng AJ, Chang JT. (2008, 3) Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer 112: 1066-1075.
  16. Liao CT, Chang JT, Wang HM, NgSH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. (2008, 3) Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol 15: 912-922.
  17. Liao CT, Chang JT, Wang HM, NgSH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. (2008, 1) Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: How and when? Cancer 112: 94-103.
  18. Lee LA, Cheng AJ, Fang TJ, Huang CG, Liao CT, Chang JT, Li HY. (2008, 1) High incidence of malignant transformation of laryngeal papilloma in Taiwan. Laryngoscope 118: 50-55.
  19. Chen YJ, Cheng AJ*. (2007, 12) Desmosome proteins play roles in carcinogenesis. J Stomatol Invest 1: 69-71.
  20. Chang JT, Chen CJ, Lin YC, Chen YC, Lin CY, Cheng AJ. (2007, 9) Health-related quality of life and patient satisfaction after treatment for breast cancer in northern Taiwan. Int J Radiat Oncol Biol Phys 69: 49-53.
  21. Chang JTC, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT, Wang TH, Lee LY, Cheng AJ*. (2007, 8) Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 6: 2271-2279.
  22. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC. (2007, 8) Survival in squamous cell carcinoma of the oral cavity: differences between pT4 N0 and other stage IVA categories. Cancer 110: 564-571.
  23. Chen YJ, Chang JT, Lee Ly, Wang HM, Liao CT, Chiu CC, Chen PJ,Cheng AJ*. (2007, 1) DSG3 is over- expressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 26: 467-476.
  24. Fan KH, Lin CY, Kang CJ, Huang SF, Wang HM, Chen EY, Chen IH, Liao CT, Cheng AJ, Chang JT. (2007, 2) Combined-modality treatment for advanced oral tongue squamous cell carcinoma. Int J Radiat Oncol Biol Phys 67: 453-461.
  25. Liao CT, Kang CJ, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Cheng AJ, Chen IH, Huang SF, Yen TC. (2007, 2) Survival of second and multiple primary tumors in patients with oral cavity squamous cell carcinoma in the betel quid chewing area. Oral Oncol 43: 811-819.
  26. Chang JTC, Chen LC, Wei SY, Chen YJ, Wang HM, Liao CT, Chen IH, Cheng AJ*. (2006, 12) Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry - plasma peptidomes from nasopharyngeal cancer patients for example. Clin Biochem 39: 1144-1151.
  27. Yen TC, Lin CY, Wang HM, Huang SF, Liao CT, Kang CJ, Ng SH, Chan SC, Fan KH, Chen IH, Lin WJ, Cheng AJ, Chang JT. (2006, 8) (18)F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 65: 1307-1341.
  28. Chang JT, Lu YC, Chen YJ, Tseng CP, Chen YL, Fang CW, Cheng AJ*. (2006, 3) hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. Br J Cancer 94:870-874.
  29. Cheng AJ*, Chen LC, Chien KY, Chen JY, Chang JTC, Wang HM, Liao CT, Chen IH. (2005, 12) Oral cancer plasma tumor marker identified with bead-based affinity fractionated proteomic technology. Clin Chem 51:2236-2244.
  30. Chang JT, Huei-Ting Yang, Wang TCV, Cheng AJ*. (2005, 11) Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells. Mol Carcinog 44:183-192.
  31. Chang JT, Lin CY, Chen TM, Kang CJ, Ng SH, Chen IH, Wang HM,Cheng AJ, Liao CT. (2005, 10) Nasopharyngeal carcinoam with cranial nerve palsy: the importance of MRI fro radiotherapy. Int J Radiat Oncol Biol Phys 63:1354-1360.
  32. Chang JT, Chang KW, Chen WH, Wang HM, Hsu YM, Yung BYM, Chen IH, Liao CY, Chen TM, Hsieh LL, Cheng AJ*. (2005, 5) Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): over-expression of NPM, CDK1, NDRG1 and under- expression of CHES1. Int J Cancer 114: 942-949.
  33. Hsieh LL, Huang TH, Chen IH, Liao CT, Wang HM, Lai CH, Liou SH, Chang JT, Cheng AJ. (2005, 1) p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer 92: 30-35.